MFLRC Academy is live. On-demand regulatory training. Lesson 1 is free. Explore→

MFLRC Academy — on-demand training in Health Canada licensing, GMP and quality systems. Browse courses →

MFLRC - MF License & Regulatory Consultants

November 15, 2026 · Regulatory Affairs

Health Canada Stops Publishing Initial Inspection Deficiencies: What It Means for Supplier Qualification

By Mussarat Fatima

Regulatory AffairsQuality AssuranceComplianceGMP
Health Canada Stops Publishing Initial Inspection Deficiencies: What It Means for Supplier Qualification

For years, the quickest way to check whether a Canadian contract manufacturer had a clean inspection history was to open Health Canada's public inspections database and read the deficiencies. That window has now narrowed. On 21 October 2026, Health Canada stopped publicly posting Initial Inspection Deficiencies, often shortened to IIDs, in the Drug and Health Products Inspections Database. The change was confirmed in Drug Establishment Licensing Bulletin 197, dated 26 October 2026, and in Natural Health Products Site Licensing and Good Manufacturing Practices Inspection Bulletin No. 12, dated 2 November 2026.

If your company relied on those preliminary deficiency summaries to screen suppliers, qualify a new contract manufacturer, or benchmark your own site, you have lost a free due diligence tool. This article explains exactly what changed, what the database still shows, and the practical steps regulated companies in Canada should take to keep their supplier qualification programs defensible.

What changed, in one answer

Health Canada has discontinued the public posting of Initial Inspection Deficiencies in the Drug and Health Products Inspections Database, effective 21 October 2026. IIDs were preliminary summaries of deficiencies identified during an inspection, published before the inspector's observations were finalized. Health Canada will no longer post them for drug GMP, natural health product GMP and Good Pharmacovigilance Practices inspections. The database continues to publish finalized inspection outcomes, including compliant and non-compliant ratings.

According to Bulletin 197, the goal is to focus public reporting on substantiated regulatory compliance information and definitive inspection findings. Health Canada frames the move as refining transparency rather than reducing it, on the basis that inspection report cards and final outcomes give a more complete and validated picture than preliminary deficiencies that may change before an inspection closes.

What are Initial Inspection Deficiencies (IIDs)?

Initial Inspection Deficiencies are summaries of the shortcomings an inspector identifies during an inspection of a regulated establishment. Health Canada introduced them in 2015 as part of a broader push toward inspection transparency. The key word is initial. An IID reflected what the inspector saw before Health Canada finalized its observations, so a listed deficiency could be downgraded, reclassified or resolved by the time the inspection was closed and a final rating assigned.

That preliminary nature is the reason Health Canada gives for discontinuing them. The department says final inspection outcomes and report cards, which have matured since 2015, now carry accurate, validated and interpretable information, while IIDs could be read out of context.

What the DHPID still shows, and what it no longer shows

The database has not gone dark. Health Canada continues to publicly report the inspections it conducts and the finalized compliance outcomes of those inspections. What disappears is the preliminary deficiency detail.

Still published in the DHPIDNo longer published
Inspections conducted and their datesInitial Inspection Deficiencies (IIDs)
Finalized compliance outcomesPreliminary deficiency summaries posted before findings are final
Compliant and non-compliant ratingsEarly, unvalidated observation detail
Inspection report cards and existing transparency mechanismsDeficiency level data for drug GMP, NHP GMP and GVP inspections

In practical terms, you can still learn whether a site was inspected and whether Health Canada rated it compliant or non-compliant. What you cannot see anymore is the granular list of what went wrong during the inspection.

Which inspection programs are affected

The discontinuation applies to three inspection programs named in the bulletin: drug Good Manufacturing Practices inspections, natural health product GMP inspections, and Good Pharmacovigilance Practices inspections. The bulletin does not extend the change to other programs, so companies should not assume it covers medical devices or cannabis unless Health Canada says so.

This scope matters for importers and brand owners who qualify a mix of suppliers. A single contract manufacturer may hold a drug establishment licence and a natural health product site licence, and both of those GMP inspection records are now reported only at the finalized outcome level.

Why this matters for supplier qualification

No new obligation falls on licence holders because of this change. The risk is informational. Buyers, importers and brand owners lose an early, free signal about problems at their suppliers. A preliminary deficiency that once appeared in the database months before a final rating now stays private until, and unless, it is reflected in a finalized outcome.

That gap pushes the weight of supplier oversight back onto the buyer. If you cannot see a supplier's deficiencies in a public database, you have to generate that intelligence yourself, through audits, questionnaires, document review and strong quality agreements. This is the same discipline Health Canada expects when it inspects your own site and asks how you built and monitor your supplier qualification program.

The timing is worth noting. While Health Canada narrows the deficiency detail it publishes, the United States Food and Drug Administration has moved in the opposite direction, toward publishing more inspection records. Canadian exporters should not assume the two systems behave the same way.

What companies should do now

Treat the loss of public IID data as a prompt to strengthen the parts of supplier qualification you control. The following steps keep your program defensible.

  • Rebuild your approved supplier list on risk, not on public data. Tier suppliers by the risk their product and process present, and set audit depth accordingly.
  • Schedule supplier and contract manufacturer audits. An on-site or thorough remote audit now replaces the deficiency detail you used to read for free.
  • Use detailed supplier questionnaires. Ask directly about recent inspection outcomes, open deficiencies, CAPA status and any terms and conditions on the licence.
  • Strengthen quality agreements. Define change notification, the right to audit, and the obligation to disclose inspection findings and regulatory actions. Our guide to quality agreement clauses inspectors expect is a useful starting point.
  • Verify the licence, not just the logo. Confirm the supplier holds a valid drug establishment licence or NHP site licence for the activity, and check the finalized compliance rating that the DHPID still publishes.
  • Run mock inspections on critical sites and on your own operation. A mock inspection surfaces a weak quality system before an inspector or a recall finds it.
  • Document your due diligence. Keep the questionnaire, the audit report, the quality agreement and your approval decision on file, so you can show how you qualified a supplier without public deficiency data.

A supplier qualification compliance checklist

Use this short checklist to confirm a supplier file would stand up to an inspector who asks how you qualified and monitor the site.

  • Confirm each supplier's licence type and status for the activity you use them for.
  • Record the current compliant or non-compliant rating from the DHPID finalized outcomes.
  • Hold a signed quality agreement with change notification and right to audit clauses.
  • Complete a supplier questionnaire within the last 12 to 24 months.
  • Complete an audit at a frequency matched to the supplier's risk tier.
  • Keep evidence of CAPA follow-up for any finding you identified.
  • Re-qualify suppliers on a defined schedule, not only when a problem appears.

Common mistakes to avoid

  • Relying on a public database as your primary supplier screen. Public ratings are a starting point, not a qualification program.
  • Treating a compliant rating as a guarantee. A compliant site can still have had deficiencies that were resolved, and conditions can change between inspections.
  • Qualifying a supplier once and never re-checking. Supplier status drifts, and without public IIDs you will not get a free early warning.
  • Leaving quality agreements silent on disclosure. If the agreement does not require the supplier to tell you about inspection findings, you may be the last to know.
  • Confusing a site licence with product compliance. A valid licence authorizes activities, it does not certify every lot.

How MFLRC can help

MF License and Regulatory Consultants helps pharmaceutical, natural health product and cosmetic companies build supplier qualification programs that do not depend on public inspection data. Our team designs risk-tiered approved supplier lists, runs supplier and contract manufacturer audits, drafts and reviews quality agreements, conducts mock GMP inspections, and prepares teams to respond to inspection findings. With more than twenty years of quality assurance and regulatory experience, and a Health Canada security-cleared, approved Quality Assurance Person on the team, MFLRC turns the loss of a public tool into a stronger, inspection-ready process.

Public inspection data no longer tells you the full story about your suppliers. Book an MFLRC supplier qualification review and know exactly where your contract manufacturers stand before your next Health Canada inspection.

Frequently asked questions

When did Health Canada stop publishing Initial Inspection Deficiencies?

Public posting of IIDs was discontinued effective 21 October 2026, as confirmed in Drug Establishment Licensing Bulletin 197 dated 26 October 2026 and NHP Site Licensing and GMP Inspection Bulletin No. 12 dated 2 November 2026.

Which inspections are affected by the change?

Drug GMP inspections, natural health product GMP inspections, and Good Pharmacovigilance Practices inspections. The bulletin does not apply the change to other programs such as medical devices or cannabis.

Can I still see whether a Canadian site passed its inspection?

Yes. Health Canada continues to publish finalized compliance outcomes, including compliant and non-compliant ratings, and inspection report cards. You simply cannot see the preliminary deficiency detail anymore.

Why did Health Canada make this change?

Health Canada says it wants public reporting to focus on substantiated, finalized findings rather than preliminary deficiencies that may change before an inspection closes. It describes the move as refining transparency, not reducing it.

How do I qualify a contract manufacturer now that deficiency data is private?

Use a layered approach: verify the licence and finalized rating, send a detailed supplier questionnaire, audit the site at a frequency set by risk, and lock disclosure and change-notification obligations into a quality agreement. Document every step.

Does this change my obligations as a licence holder?

No. The change imposes no new legal obligation. It removes a public information source, which raises the practical importance of your own supplier oversight and your ability to show how you qualified each supplier.

Conclusion

Health Canada's decision to stop posting Initial Inspection Deficiencies closes a convenient window into supplier performance. It does not change what regulators expect of you. The companies that will feel this least are the ones that already qualify suppliers through audits, questionnaires and enforceable quality agreements rather than a public database. The companies that relied on that free signal now have a clear reason to formalize their supplier qualification programs, before a weak link becomes a recall or an inspection finding.

Sources and references

Downloadable Resource

Supplier Qualification Without Public Inspection Data: A 7-Point Checklist

A practical, branded checklist to qualify and monitor contract manufacturers and testing labs now that Health Canada no longer posts initial inspection deficiencies.

File: MFLRC-Supplier-Qualification-Checklist.pdf

Share with others

Tags

Supplier QualificationInspection ReadinessDrug Establishment LicenceNHP GMPHealth CanadaContract ManufacturingQAP (Quality Assurance Person)
Book a consultation